Abstracts Archive - Page 1119 of 2425 - ACR Meeting Abstracts

Abstract Number: 1716 • 2018 ACR/ARHP Annual Meeting
Evaluation of American College of Rheumatology Provisional Composite Response Index in Systemic Sclerosis in a Phase II Trial of Abatacept Vs. Placebo
Dinesh Khanna¹ and Cathie Spino², ¹Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, ²Biostatistics, University of Michigan, Ann Arbor, MI
Background/Purpose: Treatment with CTLA4Ig, abatacept (ABA), in early diffuse cutaneous systemic sclerosis (dcSSc; the Phase 2 ASSETtrial) showed evidence of improvements in modified Rodnan skin…
Abstract Number: 1717 • 2018 ACR/ARHP Annual Meeting
Expert Consensus on the Screening, Treatment, and Management of Patients with Systemic Sclerosis-Interstitial Lung Disease, and the Potential Role of Anti-Fibrotics in a Treatment Paradigm for Systemic Sclerosis-Interstitial Lung Disease: A Delphi Consensus Study
Dinesh Khanna^1,2, Mary Strek³, Brian Southern⁴, Rajan Saggar⁵, Vivien Hsu⁶, Maureen D. Mayes⁷, Rick Silver⁸, Virginia D. Steen⁹, Donald Zoz¹⁰ and Franck Rahaghi¹¹, ¹Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, ²Division of Rheumatology, University of Michigan, Ann Arbor, MI, ³Pulmonology, University of Chicago, Chicago, IL, ⁴Pulmonology, Cleveland Clinic Ohio, Cleavland, OH, ⁵Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁶Rheumatology, Robert Wood Johnson University Scleroderma Program, New Brunswick, NJ, ⁷Rheumatology, University of Texas Medical School at Houston, Houston, TX, ⁸Rheumatology, Medical University of SC, Charleston, SC, ⁹Dept of Rheumatology, Georgetown Univ Medical Center, Washington, DC, ¹⁰Pulmonology, Boehringer Ingelheim, Ridgefield, CT, ¹¹Cleveland Clinic Florida Weston, Weston, FL
Background/Purpose: Systemic sclerosis (SSc), or scleroderma, is a rare, autoimmune, multisystem connective tissue disorder characterized by vascular damage, autoimmunity, and fibrosis of the skin and…
Abstract Number: 1718 • 2018 ACR/ARHP Annual Meeting
Skin Gene Expression Profiling Predicts Longitudinal Modified Rodnan Skin Score Change
Chase Correia¹, Mary A. Carns², Kathleen Aren², Monique Hinchcliff³ and J. Matthew Mahoney⁴, ¹Rheumatology, Northwestern Feinberg School of Medicine, Chicago, IL, ²Northwestern University, Feinberg School of Medicine Scleroderma Program, Chicago, IL, ³Rheumatology, Northwestern University, Chicago, IL, ⁴Neurological Sciences, University of Vermont College of Medicine, Burlington, VT
Background/Purpose: Systemic sclerosis (SSc) causes varying degrees of skin fibrosis with varying trajectory. Extent of skin involvement is measured by the modified Rodnan skin score…
Abstract Number: 1719 • 2018 ACR/ARHP Annual Meeting
High-Throughput Quantitative Histology in Systemic Sclerosis Skin Disease Using Computer Vision
Chase Correia¹, Seamus Mawe², Mary A. Carns³, Kathleen Aren³, Aileen Hoffman⁴, Monique Hinchcliff⁵ and J. Matthew Mahoney⁶, ¹Northwestern University, Chicago, IL, ²Department of Neurological Sciences, University of Vermont Larner College of Medicine, Burlington, VT, ³Northwestern University, Feinberg School of Medicine Scleroderma Program, Chicago, IL, ⁴Northwestern Feinberg School of Medicine, Chicago, IL, ⁵Rheumatology, Northwestern University, Chicago, IL, ⁶Neurological Sciences, University of Vermont College of Medicine, Burlington, VT
Background/Purpose: The lack of a reproducible and quantitative method to accurately assess histological skin fibrosis in patients with systemic sclerosis (SSc) has long plagued clinical…
Abstract Number: 1720 • 2018 ACR/ARHP Annual Meeting
Higher Neutrophil Count Predicts More Severe Skin/Lung Disease and Increased Mortality in Early Systemic Sclerosis
Rana Taherian¹, Vishnu Mohan¹, Jun Ying², Samuel Theodore¹, Julio Charles¹, Hau Pham¹, Minghua Wu³, Maureen D. Mayes³ and Shervin Assassi³, ¹University of Texas Health Science Center at Houston, Houston, TX, ²Department of Internal Medicine - Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, ³Rheumatology, University of Texas Health Science Center at Houston, Houston, TX
Background/Purpose: Our recent global blood transcript studies show that systemic sclerosis (SSc) patients have a prominent neutrophil signature. Mechanistic studies with neutrophils are hampered by…
Abstract Number: 1721 • 2018 ACR/ARHP Annual Meeting
Racial Differences in SSc Disease Presentation: A Cross-Sectional European Scleroderma Trials and Research Group Study
Veronika K. Jaeger¹, Elise Siegert², Eric Hachulla³, Paolo Airò⁴, Gabriele Valentini⁵, Marco Matucci-Cerinic⁶, Oliver Distler⁷, Franco Cozzi⁸, Yannick Allanore⁹, Mangtao Li¹⁰, Mohammed Tikly¹¹ and Ulrich A. Walker¹, ¹Department of Rheumatology, University Hospital Basel, Basel, Switzerland, ²Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, Berlin, Germany, ³Department of Internal Medicine and Clinical Immunology, Hôpital Claude Huriez, University of Lille, Lille, France, ⁴Rheumatology and Clinical immunology Unit, Spedali Civili of Brescia, Brescia, Italy, ⁵Second University of Naples, Naples, Italy, ⁶Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, ⁷Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ⁸Division of Rheumatology, Rheumatology Unit, Department of Medicine, University of Padova, Padova, Italy, ⁹Immunogenetics, Cochin Institute, Paris, France, ¹⁰Peking Union Medical College Hospital, Beijing, China, ¹¹Division of Rheumatology, Department of Internal Medicine, Chris Hani Baragwanath Hospital and University of the Witwatersrand, Johannesburg, South Africa
Background/Purpose: Genetic and environmental factors play a significant role in SSc. African Americans are known for a higher SSc incidence, an earlier age of onset,…
Abstract Number: 1722 • 2018 ACR/ARHP Annual Meeting
Patient-Level Factors Associated with Hospital Readmission Among Patients with Systemic Sclerosis Associated Pulmonary Hypertension
Kimberly Showalter¹, Laura Pinheiro², Jackie Szymonifka³, Irina Sobol⁴, Virginia D. Steen⁵ and Jessica K. Gordon¹, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Internal Medicine, Weill Cornell Medicine, New York, NY, ³Hospital for Special Surgery, New York, NY, ⁴Cardiology, Weill Cornell Medicine, New York, NY, ⁵Rheumatology, MedStar Georgetown University Hospital, Washington, DC
Background/Purpose: Repeat hospitalizations in patients with pulmonary hypertension from all causes are associated with worse survival. However, predictors of systemic sclerosis associated pulmonary hypertension (SSc-PH)…
Abstract Number: 1723 • 2018 ACR/ARHP Annual Meeting
Intensified B-Cell Depletion Therapy in Progressive Systemic Sclerosis Patients: 24 Months Follow-up
Daniela Rossi¹, Irene Cecchi², Massimo Radin³, Elena Rubini⁴, Savino Sciascia⁵ and Dario Roccatello⁶, ¹Department of Medicine and Experimental Oncology, CMID - Center of Research of Immunopathology and Rare Diseases, Turin, Italy, ²Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ³Department of Clinical and Biological Sciences, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ⁴Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bosco Hospital, Turin, Italy., Turin, Italy, ⁵Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Torino, Italy, ⁶Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bo, Turin, Italy
Background/Purpose:Systemic sclerosis (SSc) is a connective tissue autoimmune disease with systemic involvement and a serious medical condition with a high rate of mortality, especially due…
Abstract Number: 1724 • 2018 ACR/ARHP Annual Meeting
Effectiveness and Safety of Rituximab for the Treatment of Refractory Systemic Sclerosis Associated Calcinosis: A Case Series
Francisco Javier Narváez¹, Juan Pablo Pirola², Judit Lluch³, Pablo Juárez³, Isabel Morales³ and Joan Miquel Nolla³, ¹Rheumatology Department, Hospital de Bellvitge. Barcelona. Spain, L’Hospitalet de Llobregat, Spain, ²Rheumatology, Hospital Privado Centro Médico de Córdoba, Cordoba, Argentina, ³Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain
Background/Purpose: To analyze the effectiveness and safety of rituximab (RTX) for the treatment of refractory systemic sclerosis (SSc)–associated calcinosis. Methods: We undertook an observational study…
Abstract Number: 1725 • 2018 ACR/ARHP Annual Meeting
Fecal Microbiota Transplantation in Patients with Systemic Sclerosis- a Pilot Study
Håvard Fretheim¹, Oyvind Midtvedt¹, Anders Heiervang Tennøe¹, Henriette Didriksen¹, Torhild Garen¹, Espen Bækkevold¹, Johannes R. Hov¹, Knut EA Lundin², Marius Trøseid¹, Øyvind Molberg¹ and Anna-Maria Hoffmann-Vold¹, ¹Oslo University Hospital, Oslo, Norway, ²Dept of gastroenterology, Oslo University Hospital, Oslo, Norway
Background/Purpose: Up to 90% of patients with systemic sclerosis (SSc) have symptoms from the gastrointestinal (GI) tract. Earlier studies have shown a distinct alteration of…
Abstract Number: 1726 • 2018 ACR/ARHP Annual Meeting
Sexual Dysfunction in Systemic Sclerosis Female Patients
Barbora Hermankova^1,2, Maja Spiritovic^1,2, Hana Smucrova², Sabina Oreska^2,3, Hana Storkanova^2,3, Karel Pavelka^3,4, Jiri Vencovsky^2,5, Ladislav Šenolt^2,3, Radim Becvar^2,3 and Michal Tomcik^2,3, ¹Department of Physiotherapy, Faculty of Physical Education and Sports, Charles University, Prague, Czech Republic, Prague, Czech Republic, ²Institute of Rheumatology, Prague, Czech Republic, Prague, Czech Republic, ³Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁴Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁵Department Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic
Background/Purpose: Systemic sclerosis (SSc) is a chronic autoimmune disease leading to various physical and psychological impairments including sexual dysfunction. The aim of this study was…
Abstract Number: 1727 • 2018 ACR/ARHP Annual Meeting
Prospective Confirmation of Potential Link between Proton Pump Inhibitor Exposure and Calcinosis in Systemic Sclerosis
Lauren V. Host¹, Corrado Campochiaro¹, Svetlana I. Nihtyanova², Christopher P. Denton³ and Voon H. Ong¹, ¹Rheumatology and Connective Tissue Diseases, University College London, Royal Free Hospital, London, United Kingdom, ²Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom, ³University College London, London, United Kingdom
Background/Purpose: Long-term use of proton pump inhibitors (PPI) have been linked to safety concerns. In a previous retrospective analysis, a potential association between PPI use…
Abstract Number: 1728 • 2018 ACR/ARHP Annual Meeting
Pharmacokinetics of Cyclophosphamide in Scleroderma Treated By Cyclophosphamide Versus Transplantation
David Adams¹, Keith Sullivan², Ivan Spasojevic¹, Ping Fan¹, Mario Sampson³, Michael Cohen-Wolkowiez³, E. William St Clair⁴, Rob Woolson⁵, Jan Storek⁶, Mary Ellen Csuka⁷, Ashley Pinckney⁵, Beverly Welch⁸, Ellen Goldmuntz⁹, Daniel E. Furst¹⁰, Leslie Crofford¹¹, Lynette Keyes-Elstein¹², Maureen Mayes¹³, Peter McSweeney¹⁴ and Richard Nash¹⁴, ¹Medicine, Duke University Medical Center, Durham, NC, ²Duke University Medical Center, Durham, NC, ³Pediatrics-Infectious Disease, Duke University Medical Center, Durham, NC, ⁴Rheumatology, Duke University Medical Center, Durham, NC, ⁵Rho Federal Systems, Inc., Chapel Hill, NC, ⁶University of Calgary, Calgary, AB, Canada, ⁷Medicine, Medical College of Wisconsin, Milwaukee, WI, ⁸National Institutes of Health, Bethesda, MD, ⁹NIAID, NIH, Bethesda, MD, ¹⁰University of Washington, Seattle, WA, ¹¹Division of Rheumatology and Immunology, Vanderbilt University Medical Center, Nashville, TN, ¹²Clinical Statistics, Rho Federal Systems, Inc., Chapel Hill, NC, ¹³Rheumatology, University of Texas at Houston, Houston, TX, ¹⁴Colorado Blood Cancer Institute, Denver, CO
Background/Purpose: The pharmacokinetics (PK) of cyclophosphamide (CP) and its primary active metabolite, 4-hydroxycyclophosphamide (4-OH-CP) have not been adequately studied in scleroderma. The hypothesis of this…
Abstract Number: 1729 • 2018 ACR/ARHP Annual Meeting
Increased Risk of Valvular Heart Disease in Patients with Systemic Sclerosis: Results from a Population-Based Cohort (1980-2016)
Reto Kurmann¹, Avneek Singh Sandhu², Cynthia S. Crowson³, Rekha Mankad¹, Thomas Osborn², Kenneth J. Warrington⁴ and Ashima Makol², ¹Cardiovascular Diseases, Mayo Clinic College of Medicine and Science, Rochester, MN, ²Rheumatology, Mayo Clinic, Rochester, MN, ³Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN, ⁴Rheumatology, Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, MN
Background/Purpose: Systemic Sclerosis (SSc) is a complex, heterogenous autoimmune disease characterized by microvascular injury and widespread fibrosis of the skin and internal organs, particularly lungs…
Abstract Number: 1730 • 2018 ACR/ARHP Annual Meeting
A Role for Duplex Ultrasound of Hand Arteries in the Assessment of the Vasculopathy Associated to Systemic Sclerosis-like Diseases
Silvia Pérez Esteban¹, Esperanza Naredo Sánchez¹, Sheila Recuero Díaz¹, Fredeswinda I. Romero-Bueno², Gabriel Herrero-Beaumont³ and Olga Sanchez-Pernaute⁴, ¹Rheumatology, Fundación Jiménez Díaz University Hospital & Health Research Institute, Madrid, Spain, ²Section for Autoimmune Diseases, Rheumatology, Fundación Jiménez Díaz University Hospital & Health Research Institute, Madrid, Spain, ³Bone and Joint Research Unit, Fundación Jiménez Díaz University Hospital & Health Research Institute, Madrid, Spain, ⁴Rheumatology Division. Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
Background/Purpose: Small vessel arteriopathy precedes the development of organ damage and tissue fibrosis in systemic sclerosis (SSc) and related disorders. It is currently considered that…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].